Last reviewed · How we verify
CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion is a Small molecule drug developed by Famewave Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion |
|---|---|
| Sponsor | Famewave Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion CI brief — competitive landscape report
- CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion updates RSS · CI watch RSS
- Famewave Ltd. portfolio CI
Frequently asked questions about CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
What is CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion?
CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion is a Small molecule drug developed by Famewave Ltd..
Who makes CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion?
CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion is developed by Famewave Ltd. (see full Famewave Ltd. pipeline at /company/famewave-ltd).
What development phase is CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion in?
CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion is in Phase 1.